September 16, 2019 / 12:58 PM / a month ago

BRIEF-Amplyx Pharmaceuticals Executed Exclusive Worldwide License Agreement With Novartis

Sept 16 (Reuters) - Novartis AG:

* AMPLYX PHARMACEUTICALS - EXECUTED EXCLUSIVE WORLDWIDE LICENSE AGREEMENT WITH NOVARTIS

* AMPLYX PHARMACEUTICAL - UNDER AGREEMENT CO ACQUIRED RIGHTS TO PHASE 2 ANTI-BK VIRUS MONOCLONAL ANTIBODY, MAU868, FOR TREATMENT, PREVENTION OF BKV DISEASE

* AMPLYX PHARMACEUTICALS - FINANCIAL TERMS HAVE NOT BEEN DISCLOSED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below